Peter C Gotzsche
Overview
Explore the profile of Peter C Gotzsche including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
316
Citations
77415
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boesen K, Saiz L, Gotzsche P, Erviti J
Circ Cardiovasc Qual Outcomes
. 2025 Feb;
:e011321.
PMID: 39907009
No abstract available.
2.
Ponnou S, Timimi S, Briffault X, Batstra L, Gotzsche P, Gonon F
Lancet Psychiatry
. 2024 Jan;
11(2):92-93.
PMID: 38245022
No abstract available.
3.
Gotzsche P, Demasi M
Int J Risk Saf Med
. 2023 Sep;
35(2):103-116.
PMID: 37718853
Background: Depression drugs can be difficult to come off due to withdrawal symptoms. Gradual tapering with tapering support is needed to help patients withdraw safely. Objective: To review the withdrawal...
4.
Junqueira D, Zorzela L, Golder S, Loke Y, Gagnier J, Julious S, et al.
J Clin Epidemiol
. 2023 Apr;
158:149-165.
PMID: 37100738
Randomized controlled trials remain the reference standard for healthcare research on effects of interventions, and the need to report both benefits and harms is essential. The Consolidated Standards of Reporting...
5.
Junqueira D, Zorzela L, Golder S, Loke Y, Gagnier J, Julious S, et al.
BMJ
. 2023 Apr;
381:e073725.
PMID: 37094878
No abstract available.
6.
7.
Gotzsche P
Indian J Med Ethics
. 2022 Aug;
VII(3):189-193.
PMID: 36043261
Anonymous sources are used by journalists when it is important to protect whistleblowers from repercussions. Healthcare is heavily influenced by vested interests which are often financial, but academic prestige and...
8.
Gotzsche P, Healy D
Int J Risk Saf Med
. 2022 Jul;
33(4):385-408.
PMID: 35786661
Background: Fluoxetine was approved for depression in children and adolescents based on two placebo-controlled trials, X065 and HCJE, with 96 and 219 participants, respectively. Objective: To review these trials, which...
9.
Gotzsche P
Indian J Med Ethics
. 2022 Jun;
VII(3):254.
PMID: 35695872
It has been widely suspected that SARS-CoV-2, the coronavirus that caused the Covid-19 pandemic, escaped from the Wuhan Institute of Virology because of sloppy safety procedures and that it was...
10.
Boesen K, Paludan-Muller A, Gotzsche P, Jorgensen K
Cochrane Database Syst Rev
. 2022 Feb;
2:CD012857.
PMID: 35201607
Background: Attention deficit hyperactivity disorder (ADHD) is a psychiatric diagnosis increasingly used in adults. The recommended first-line pharmacological treatment is central nervous system (CNS) stimulants, such as methylphenidate, but uncertainty...